BioArctic AB (BioArctic AB) ROCE % : -22.02% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is BioArctic AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioArctic AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -22.02%.

BioArctic AB ROCE % Historical Data

The historical data trend for BioArctic AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioArctic AB ROCE % Chart

BioArctic AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

10.71

-9.22

-15.35

-1.25

30.10

BioArctic AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															130.16	-38.21	52.33	-29.32	-22.02

BioArctic AB ROCE % Calculation

BioArctic AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	26.986	/	( ( (82.704 - 6.83)	+	(115.629 - 12.183) )	/ 2 )
	=	26.986	/	( (75.874	+	103.446)	/ 2 )
	=	26.986	/	89.66
	=	30.10 %

BioArctic AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-22.044	/	( ( (115.629 - 12.183)	+	(109.144 - 12.375) )	/ 2 )
	=	-22.044	/	( ( 103.446	+	96.769 )	/ 2 )
	=	-22.044	/	100.1075
	=	-22.02 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

BioArctic AB (OTCPK:BRCTF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioArctic AB ROCE % Related Terms

Thank you for viewing the detailed overview of BioArctic AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioArctic AB (BioArctic AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (OTCPK:BRCTF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BIOA B:Sweden 0RV2:UK B9A:Germany

Address

Warfvinges vag 35, Stockholm, SWE, SE-112 51

Website

https://www.bioarctic.se

BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.